Matrix of consultees and commentators

<table>
<thead>
<tr>
<th>Consultees</th>
<th>Commentators (no right to submit or appeal)</th>
</tr>
</thead>
</table>
| Manufacturers/sponsors  
  - Amgen (denosumab) | General  
  - Board of Community Health Councils in Wales  
  - British National Formulary  
  - Care Quality Commission  
  - Commissioning Support Appraisals Services  
  - Department of Health, Social Services and Public Safety for Northern Ireland  
  - Medicines and Healthcare products Regulatory Agency  
  - National Association of Primary Care  
  - NHS Alliance  
  - NHS Commercial Medicines Unit  
  - NHS Confederation  
  - NHS Quality Improvement Scotland  
  - Public Health Wales NHS Trust  
  - Scottish Medicines Consortium |
| Patient/carer groups  
  - Afiya Trust  
  - Black Health Agency  
  - Bob Champion Cancer Trust  
  - Breakthrough Breast Cancer  
  - Breast Cancer Campaign  
  - Breast Cancer Care  
  - Breast Cancer Haven  
  - Breast Cancer UK  
  - British Kidney Patient Association  
  - British Lung Foundation  
  - Cancer 52  
  - Cancer Black Care  
  - Cancer Equality  
  - CANCERactive  
  - Chinese National Healthy Living Centre  
  - Counsel and Care  
  - Equalities National Council  
  - Everyman  
  - HALT - Help Against Liver Tumours  
  - Helen Rollason Heal Cancer Charity  
  - James Whale Fund for Kidney Cancer  
  - Kidney Alliance  
  - Kidney Research UK  
  - Leonard Cheshire Disability  
  - Leukaemia CARE  
  - Leukaemia Society (UK)  
  - Macmillan Cancer Support  
  - Maggie’s Centres  
  - Marie Curie Cancer Care  
  - Muslim Council of Britain  
  - Muslim Health Network  
| Comparator manufacturers  
  - Bayer Schering (disodium clodronate)  
  - Beacon Pharmaceuticals (disodium clodronate)  
  - Hospira UK (disodium pamidronate)  
  - Medac UK (disodium pamidronate)  
  - Novartis (disodium pamidronate, zoledronic acid)  
  - Roche (disodium clodronate, ibandronic acid)  
  - Wockhardt (disodium pamidronate)  
| Relevant research groups  
  - Against Breast Cancer Research Group  
  - Bone Research Society  
  - Breast Cancer Hope  
  - Breast Cancer Research Trust  

National Institute for Health and Clinical Excellence  
Matrix for the appraisal of denosumab for the treatment of bone metastases from solid tumours and multiple myeloma  
Issue date: March 2010
<table>
<thead>
<tr>
<th>Consultees</th>
<th>Commentators (no right to submit or appeal)</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Myeloma UK</td>
<td>• British Prostate Group</td>
</tr>
<tr>
<td>• National Kidney Federation</td>
<td>• Cochrane Collaboration – Cochrane Breast Cancer Group</td>
</tr>
<tr>
<td>• Orchid</td>
<td>• Cochrane Prostate Diseases and Urologic Cancers Group</td>
</tr>
<tr>
<td>• PCaSO – Prostate Cancer Network</td>
<td>• CORE - Digestive Disorders Foundation</td>
</tr>
<tr>
<td>• Prostate Cancer Charity</td>
<td>• Institute of Cancer Research</td>
</tr>
<tr>
<td>• Prostate Cancer Support Federation</td>
<td>• Leukaemia &amp; Lymphoma Research</td>
</tr>
<tr>
<td>• Prostate Help Association</td>
<td>• MRC Clinical Trials Unit</td>
</tr>
<tr>
<td>• Rarer Cancers Foundation</td>
<td>• National Cancer Research Institute</td>
</tr>
<tr>
<td>• Roy Castle Lung Cancer Foundation</td>
<td>• National Cancer Research Network</td>
</tr>
<tr>
<td>• South Asian Health Foundation</td>
<td>• National Institute for Health Research</td>
</tr>
<tr>
<td>• Specialised Healthcare Alliance</td>
<td>• Ovarian and Prostate Cancer Research Trust</td>
</tr>
<tr>
<td>• Sue Ryder Care</td>
<td>• Policy Research Institute on Ageing and Ethnicity</td>
</tr>
<tr>
<td>• Tenovus</td>
<td>• Pro Cancer Research Fund</td>
</tr>
<tr>
<td>• Women’s Health Concern</td>
<td>• Prostate Action</td>
</tr>
<tr>
<td><strong>Professional groups</strong></td>
<td>• Prostate Cancer Research Centre</td>
</tr>
<tr>
<td>• Association of Cancer Physicians</td>
<td>• Research Institute for the Care of Older People</td>
</tr>
<tr>
<td>• Association of Respiratory Nurse Specialists</td>
<td><strong>Assessment Group</strong></td>
</tr>
<tr>
<td>• Association of Surgeons of Great Britain and Ireland</td>
<td>• Aberdeen Health Technology Assessment Group</td>
</tr>
<tr>
<td>• British Association for Services to the Elderly</td>
<td>• National Institute for Health Research Health Technology Assessment Programme</td>
</tr>
<tr>
<td>• British Association for the Study of the Liver</td>
<td><strong>Associated Guideline Groups</strong></td>
</tr>
<tr>
<td>• British Association of Surgical Oncology</td>
<td>• National Collaborating Centre for Cancer</td>
</tr>
<tr>
<td>• British Association of Urological Nurses</td>
<td><strong>Associated Public Health Groups</strong></td>
</tr>
<tr>
<td>• British Association of Urological Surgeons</td>
<td>• None</td>
</tr>
<tr>
<td>• British Geriatrics Society</td>
<td></td>
</tr>
<tr>
<td>• British Institute of Musculoskeletal Medicine</td>
<td></td>
</tr>
<tr>
<td>• British Institute of Radiology</td>
<td></td>
</tr>
<tr>
<td>• British Liver Nurses Forum</td>
<td></td>
</tr>
<tr>
<td>• British Oncological Association</td>
<td></td>
</tr>
<tr>
<td>• British Orthopaedic Association</td>
<td></td>
</tr>
<tr>
<td>• British Orthopaedic Oncology Society</td>
<td></td>
</tr>
<tr>
<td>• British Prostate Group</td>
<td></td>
</tr>
<tr>
<td>• British Psychosocial Oncology Society</td>
<td></td>
</tr>
<tr>
<td>• British Renal Society</td>
<td></td>
</tr>
<tr>
<td>• British Society for Haematology</td>
<td></td>
</tr>
<tr>
<td>• British Society of Rehabilitation Medicine</td>
<td></td>
</tr>
</tbody>
</table>

National Institute for Health and Clinical Excellence
Matrix for the appraisal of denosumab for the treatment of bone metastases from solid tumours and multiple myeloma
Issue date: March 2010
### Consultees

- British Society of Skeletal Radiologists
- British Thoracic Society
- British Uro-Oncology Group
- Cancer Networks Pharmacists Forum
- Cancer Research UK
- National Lung Cancer Forum for Nurses
- National Osteoporosis Society
- National Pharmacy Association
- Pelican Cancer Foundation
- Primary Care Respiratory Society
- Renal Association
- Renal Pharmacy Group
- Royal College of Anaesthetists
- Royal College of General Practitioners
- Royal College of Nursing
- Royal College of Pathologists
- Royal College of Physicians
- Royal College of Radiologists
- Royal College of Surgeons
- Royal Pharmaceutical Society
- Royal Society of Medicine
- Society and College of Radiographers
- UK Myeloma Forum
- United Kingdom Clinical Pharmacy Association
- United Kingdom Oncology Nursing Society

### Commentators (no right to submit or appeal)

- British Society of Skeletal Radiologists
- British Thoracic Society
- British Uro-Oncology Group
- Cancer Networks Pharmacists Forum
- Cancer Research UK
- National Lung Cancer Forum for Nurses
- National Osteoporosis Society
- National Pharmacy Association
- Pelican Cancer Foundation
- Primary Care Respiratory Society
- Renal Association
- Renal Pharmacy Group
- Royal College of Anaesthetists
- Royal College of General Practitioners
- Royal College of Nursing
- Royal College of Pathologists
- Royal College of Physicians
- Royal College of Radiologists
- Royal College of Surgeons
- Royal Pharmaceutical Society
- Royal Society of Medicine
- Society and College of Radiographers
- UK Myeloma Forum
- United Kingdom Clinical Pharmacy Association
- United Kingdom Oncology Nursing Society

### Others

- Department of Health
- Sheffield PCT
- Welsh Assembly Government
- West Sussex Teaching PCT

NICE is committed to promoting equality and eliminating unlawful discrimination. Please let us know if we have missed any important organisations from the lists contained within the matrix and which organisations we should include who have a particular focus on relevant equality issues.

**PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS**

National Institute for Health and Clinical Excellence
Matrix for the appraisal of denosumab for the treatment of bone metastases from solid tumours and multiple myeloma
Issue date: March 2010
Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

Consultees can participate in the consultation on the draft scope, the Assessment Report and the Appraisal Consultation Document, they are invited to prepare a submission dossier and all non-manufacturers/sponsors consultee organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee. All consultees are given the opportunity to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare a submission dossier, and that receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Information Authority and NHS Purchasing and Supplies Agency, and the British National Formulary).

All non-manufacturers/sponsors commentator organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee.

Assessment team

An independent academic group (commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist in the appraisal) prepares an Assessment Report on the health technology (a review of the clinical and cost effectiveness of the technology(ies) based on a systematic review of the literature and a review of manufacturer and sponsor submission to the Institute).